Hla type and survival in lung cancer
- 1 July 1980
Abstract
A significant positive association between antigens HLA Aw 19 and/or HLA B5 and a disease-free survival time of one year for patients with lung cancer has been reported but not confirmed. We have HLA-typed 20 white patients with non-oat-cell bronchogenic carcinoma who have survived at least a year from the time of diagnosis. Half these patients possessed these antigens (P < 0.08). This highly suggests that the presence of these antigens is associated with prolonged survival time. Now may be the time for performing large scale clinical trials using these antigens as stratification factors. Cancer 46:38–40, 1980.This publication has 5 references indexed in Scilit:
- Ifosfamide in the treatment of recurrent or disseminated lung cancerA phase II study of two dose schedulesCancer, 1978
- Subdivisions of the HLA—B5 and Bw35 ComplexTissue Antigens, 1978
- Prolonged disease-free survival in bronchogenic carcinoma associated with HLA-Aw19 and HLA-B5:A two-year prospective studyCancer, 1977
- HLA Antigens in Bronchogenic CarcinomaOncology, 1977
- Prolonged Survival in Bronchogenic Carcinoma Associated With HL-A Antigens W-19 and HL-A5: A Preliminary ReportJNCI Journal of the National Cancer Institute, 1975